Division of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla, California, USA.
COPD. 2020 Feb;17(1):34-39. doi: 10.1080/15412555.2019.1707789. Epub 2020 Jan 22.
The co-existence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA), termed the overlap syndrome (OVS), is associated with adverse outcomes that may be reversed with treatment. However, diagnosis is limited by the apparent need for in-laboratory polysomnography (PSG). WatchPAT is a portable diagnostic device that is validated for the diagnosis of OSA that might represent an attractive tool for the diagnosis of OVS.Subjects with established COPD were recruited from a general population. Subjects underwent PSG and simultaneous recording with WatchPAT. Pulmonary function testing and questionnaires were also performed.A total of 36 subjects were recruited and valid data was obtained on 33 (age 63 ± 7, BMI 28 ± 7, 61% male, FEV 56 ± 20% predicted). There was no significant difference in the apnea-hypopnea index (AHI) between PSG and WatchPAT (19 ± 20 versus 20 ± 15 events/h; mean difference 2(-2, 5) events/h; = 0.381). The AHI was not significantly different in rapid eye movement (REM) and non-rapid eye movement (NREM) determined by PSG versus REM and NREM determined by WatchPAT. WatchPAT slightly overestimated total and REM sleep time, and sleep efficiency. The sensitivity of WatchPAT at an AHI cut-off of ≥5, ≥15, and ≥30 events/h for corresponding PSG AHI cut-offs was 95.8, 92.3, and 88.9, respectively; specificity was 55, 65.0, and 95.8, respectively.WatchPAT is able to determine OSA reliably in patients with COPD. The availability of this additional diagnostic modality may lead to improved detection of OVS, which may in turn lead to improved outcomes for a group of COPD patients at high risk of poor outcomes.
慢性阻塞性肺疾病(COPD)和阻塞性睡眠呼吸暂停(OSA)并存,称为重叠综合征(OVS),与不良结局相关,这些结局可能通过治疗逆转。然而,诊断受到似乎需要在实验室进行多导睡眠图(PSG)的限制。WatchPAT 是一种经过验证可用于诊断 OSA 的便携式诊断设备,它可能是诊断 OVS 的一种有吸引力的工具。
从一般人群中招募了患有明确 COPD 的受试者。受试者接受了 PSG 和 WatchPAT 的同步记录。还进行了肺功能测试和问卷调查。
共招募了 36 名受试者,其中 33 名(年龄 63±7,BMI 28±7,61%男性,FEV 56±20%预测值)获得了有效数据。PSG 和 WatchPAT 之间的呼吸暂停低通气指数(AHI)没有显著差异(19±20 与 20±15 事件/小时;平均差异 2(-2,5)事件/小时;=0.381)。PSG 确定的 REM 和 NREM 中的 AHI 与 WatchPAT 确定的 REM 和 NREM 中的 AHI 没有显著差异。WatchPAT 略微高估了总睡眠时间和 REM 睡眠时间以及睡眠效率。当 WatchPAT 的 AHI 截断值分别为≥5、≥15 和≥30 事件/小时时,其对相应 PSG AHI 截断值的敏感性分别为 95.8、92.3 和 88.9;特异性分别为 55、65.0 和 95.8。
WatchPAT 能够可靠地确定 COPD 患者的 OSA。这种额外诊断方式的可用性可能会导致 OVS 的检出率提高,从而可能提高一组 COPD 患者的预后,这些患者的预后不良风险较高。